NASDAQ:ALLK Allakos - ALLK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.57 +0.17 (+2.30%) (As of 02/2/2023 04:29 PM ET) Add Compare Share Share Today's Range$7.39▼$7.7350-Day Range$6.95▼$8.4252-Week Range$2.54▼$8.73Volume694,538 shsAverage Volume765,534 shsMarket Capitalization$644.96 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Allakos MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside38.7% Upside$10.50 Price TargetShort InterestHealthy6.02% of Float Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.77Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.27) to ($2.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.67 out of 5 starsMedical Sector75th out of 1,030 stocksPharmaceutical Preparations Industry26th out of 502 stocks 3.0 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Allakos has a forecasted upside of 38.7% from its current price of $7.57.Amount of Analyst CoverageAllakos has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.02% of the float of Allakos has been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allakos has recently decreased by 5.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAllakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Allakos is -0.86. Previous Next 3.2 News and Social Media Coverage News SentimentAllakos has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Allakos this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat Follows2 people have added Allakos to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders33.25% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.07% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($5.27) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allakos (NASDAQ:ALLK) StockAllakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.Read More Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Sees Large Decrease in Short InterestJanuary 28, 2023 | americanbankingnews.comAllakos (NASDAQ:ALLK) Price Target Raised to $8.00 at Morgan StanleyFebruary 2, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 26, 2023 | finance.yahoo.comIs Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic ValueDecember 15, 2022 | finance.yahoo.comIs Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans?December 9, 2022 | finance.yahoo.comAllakos Inc. (ALLK) Moves to Buy: Rationale Behind the UpgradeNovember 29, 2022 | finance.yahoo.comAllakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications BiologyNovember 10, 2022 | finance.yahoo.comAllakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual MeetingFebruary 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.November 7, 2022 | finance.yahoo.comAllakos Provides Business Update and Reports Third Quarter 2022 Financial ResultsOctober 24, 2022 | reuters.comALLK.OQ - Allakos Inc | Stock Price & Latest News | ReutersOctober 20, 2022 | finance.yahoo.comPharmaEssentia USA Expands Leadership With Executive Hires in Marketing, Medical Affairs and Communications and Advocacy - Yahoo FinanceOctober 18, 2022 | seekingalpha.comAllakos: Potential For Comeback With Lirentelimab With 2 Indications (NASDAQ:ALLK) - Seeking AlphaOctober 14, 2022 | barrons.comAlkermes, Allakos, and Other Stocks See Action From Activist Investors - Barron'sSeptember 27, 2022 | marketwatch.comAllakos Shares Rise After Co. Says Chmn, Director Buy Shares - MarketWatchSeptember 26, 2022 | uk.investing.comAdobe And 2 Other Stock Insiders Are Buying By Benzinga - Investing.com UKSeptember 24, 2022 | finance.yahoo.comAfter losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gainSeptember 21, 2022 | investorplace.comWhy Is Allakos (ALLK) Stock Soaring 25% Today? - InvestorPlaceSeptember 20, 2022 | benzinga.comWhy Allakos Shares Are Rising Sharply - Allakos (NASDAQ:ALLK) - BenzingaSeptember 19, 2022 | seekingalpha.comIceCure Medical, Allakos top healthcare gainers; Virios Therapeutics lead losers' pack - Seeking AlphaSeptember 19, 2022 | uk.investing.comWhy Allakos Shares Are Rising Sharply By Benzinga - Investing.com UKSeptember 19, 2022 | investorplace.comWhy Is Allakos (ALLK) Stock Soaring 25% Today?September 19, 2022 | marketwatch.comAllakos Shares Surge After Public Offering >ALLK - MarketWatchSeptember 19, 2022 | seekingalpha.comAllakos prices ~$150M underwritten offering - Seeking AlphaSeptember 19, 2022 | finance.yahoo.comAllakos Announces Pricing of $150 Million Underwritten Offering of Common StockSeptember 12, 2022 | finance.yahoo.comAllakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)September 11, 2022 | seekingalpha.comAllakos falls as lead asset offers mixed results in late-stage trialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Company Calendar Last Earnings11/07/2022Today2/02/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees192Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$13.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+38.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.74% Return on Assets-92.48% Debt Debt-to-Equity RatioN/A Current Ratio12.30 Quick Ratio12.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.20 per share Price / Book0.92Miscellaneous Outstanding Shares85,200,000Free Float56,874,000Market Cap$644.96 million OptionableNot Optionable Beta0.46 Key ExecutivesRobert AlexanderChief Executive Officer & DirectorAdam L. TomasiPresident & Chief Operating OfficerHarlan Baird RadfordChief Financial OfficerCraig PatersonChief Medical OfficerRuby CasarenoVice President-Technical OperationsKey CompetitorsCara TherapeuticsNASDAQ:CARAMoonLake ImmunotherapeuticsNASDAQ:MLTXPhibro Animal HealthNASDAQ:PAHCEdgewise TherapeuticsNASDAQ:EWTXFulcrum TherapeuticsNASDAQ:FULCView All CompetitorsInsiders & InstitutionsBank of Montreal CanBought 121,813 shares on 2/1/2023Ownership: 0.143%Zurcher Kantonalbank Zurich Cantonalbank Bought 10,707 shares on 2/1/2023Ownership: 0.015%Bank of New York Mellon CorpBought 16,099 shares on 12/8/2022Ownership: 0.079%Anson Funds Management LPBought 35,208 shares on 11/16/2022Ownership: 0.041%Jane Street Group LLCBought 15,400 shares on 11/16/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ALLK Stock - Frequently Asked Questions Should I buy or sell Allakos stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares. View ALLK analyst ratings or view top-rated stocks. What is Allakos' stock price forecast for 2023? 4 brokerages have issued 12-month target prices for Allakos' shares. Their ALLK share price forecasts range from $8.00 to $13.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 40.2% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts. How have ALLK shares performed in 2023? Allakos' stock was trading at $8.42 at the beginning of the year. Since then, ALLK stock has decreased by 11.0% and is now trading at $7.49. View the best growth stocks for 2023 here. Are investors shorting Allakos? Allakos saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 2,810,000 shares, a drop of 5.7% from the December 31st total of 2,980,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is presently 2.6 days. Currently, 6.0% of the company's shares are sold short. View Allakos' Short Interest. When is Allakos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our ALLK earnings forecast. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) released its earnings results on Monday, November, 7th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.25. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). When did Allakos IPO? (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager. What is Allakos' stock symbol? Allakos trades on the NASDAQ under the ticker symbol "ALLK." Who are Allakos' major shareholders? Allakos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.14%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James. View institutional ownership trends. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allakos' stock price today? One share of ALLK stock can currently be purchased for approximately $7.49. How much money does Allakos make? Allakos (NASDAQ:ALLK) has a market capitalization of $638.15 million. The company earns $-269,860,000.00 in net income (profit) each year or ($6.76) on an earnings per share basis. How many employees does Allakos have? The company employs 192 workers across the globe. How can I contact Allakos? Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com. This page (NASDAQ:ALLK) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.